Aclaris Therapeutics (ACRS) Non-Current Deferred Tax Liability (2017 - 2023)
Aclaris Therapeutics (ACRS) posted quarterly Non-Current Deferred Tax Liability of $367000.0 for Q3 2023, little changed year-over-year from $367000.0 in Q3 2022, and little changed quarter-over-quarter from $367000.0 in Q2 2023.
Aclaris Therapeutics (ACRS) Non-Current Deferred Tax Liability (2017 - 2023) Analysis & Trends
Aclaris Therapeutics' Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $367000.0 for Q3 2023.
- In Q3 2023, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $367000.0; the TTM figure through Sep 2023 stood at $367000.0 (changed 0.0% YoY), while the FY2022 annual figure was $367000.0, changed 0.0% from the prior year.
- Non-Current Deferred Tax Liability for Q3 2023 stood at $367000.0, roughly flat from $367000.0 in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $549000.0 in Q1 2019, with the low at $367000.0 in Q4 2020.
- The 5-year median for Non-Current Deferred Tax Liability is $367000.0 (2020), against an average of $434052.6.
- The sharpest annual moves came in 2019 and 2020: Non-Current Deferred Tax Liability changed 0.0% in 2019, then sank 33.15% in 2020.
- Aclaris Therapeutics' Non-Current Deferred Tax Liability stood at $549000.0 in 2019, then tumbled by 33.15% to $367000.0 in 2020, then changed by 0.0% to $367000.0 in 2021, then changed by 0.0% to $367000.0 in 2022, then changed by 0.0% to $367000.0 in 2023.
- Business Quant data shows ACRS's Non-Current Deferred Tax Liability at $367000.0 in Q3 2023, $367000.0 in Q2 2023, and $367000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 367,000.00 |
| Sep 30, 2023 | 367,000.00 |
| Jun 30, 2023 | 367,000.00 |
| Jun 30, 2023 | 367,000.00 |
| Mar 31, 2023 | 367,000.00 |
| Mar 31, 2023 | 367,000.00 |
| Dec 31, 2022 | 367,000.00 |
| Dec 31, 2022 | 367,000.00 |
| Sep 30, 2022 | 367,000.00 |
| Sep 30, 2022 | 367,000.00 |
| Jun 30, 2022 | 367,000.00 |
| Jun 30, 2022 | 367,000.00 |
| Mar 31, 2022 | 367,000.00 |
| Mar 31, 2022 | 367,000.00 |
| Dec 31, 2021 | 367,000.00 |
| Dec 31, 2021 | 367,000.00 |
| Sep 30, 2021 | 367,000.00 |
| Sep 30, 2021 | 367,000.00 |
| Jun 30, 2021 | 367,000.00 |
| Jun 30, 2021 | 367,000.00 |